Idera Pharmaceuticals Announces the Issuance of US Patent Claiming Compounds that Target Toll-like Receptor 9
13 Setembro 2006 - 9:30AM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the
issuance of US patent 7,105,495 (the '495 patent) for immune
modulatory oligonucleotides (IMO(TM)) that target Toll-like
Receptor 9 (TLR9). The claims of this patent cover methods for
modulating the immunostimulatory effect of novel dinucleotide
motifs and CpG motifs by introducing modifications in the flanking
sequence. These modifications include changes to the backbone and
the nucleosides. Similar claims have been granted in Europe (EU
1,278,761) and Australia (AU 2001257366). "Idera's TLR discovery
and development programs are based on our ability to generate a
broad range of novel TLR-targeted oligonucleotides, each with
specific immune modulating characteristics", stated Sudhir Agrawal,
D. Phil., Idera's Chief Executive Officer and Chief Scientific
Officer. "The '495 patent further strengthens the intellectual
property portfolio that protects our TLR-targeted therapeutic
technology." Idera presently has over 150 patents and patent
applications world-wide covering agonists of TLR9, TLR8, and TLR7
and antagonists of TLR9. Idera's entire portfolio of DNA and
RNA-based compounds has been designed through in-house
structure-activity relationship studies. About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug discovery and
development company with a pipeline of drug candidates to treat
cancer, and infectious, respiratory, and autoimmune diseases.
Idera's proprietary drug candidates are designed to modulate TLRs,
the body's first line of immune defense. Idera's pioneering DNA
chemistry expertise enables it to identify drug candidates for
internal development and creates opportunities for multiple
collaborative alliances. Idera's most advanced clinical candidate,
IMO-2055, is an agonist of TLR9 and is currently in a Phase 2 trial
in oncology and in a Phase 1/2 chemotherapy combination trial in
oncology. Idera has selected a second TLR9 agonist, IMO-2125, as a
lead candidate for treating infectious diseases. Idera also is
collaborating with Novartis for the discovery, optimization,
development, and commercialization of additional TLR9 agonist
candidates for asthma and allergy. For more information, visit
www.iderapharma.com. Forward Looking Statements This press release
contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies will be
indicative of results that may be obtained in clinical trials;
whether the patents and patent applications owned or licensed by
Idera will protect the Company's technology and prevent others from
infringing it; whether Idera's cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera's Quarterly Report on Form 10-Q filed on August 14, 2006,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Idera Pharmaceutical (AMEX:IDP)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Idera Pharmaceutical (AMEX:IDP)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
Notícias em tempo-real sobre Idera Pharmaceuticals da American Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Idera Pharmaceuticals, Inc.